GT199900147A
(es)
*
|
1998-09-17 |
1999-09-06 |
|
1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
|
US6197786B1
(en)
*
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
US6147089A
(en)
*
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
US7115279B2
(en)
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
SE0101161D0
(sv)
*
|
2001-03-30 |
2001-03-30 |
Astrazeneca Ab |
New compounds
|
EP1385501A2
(en)
*
|
2001-04-11 |
2004-02-04 |
Atherogenics, Inc. |
Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
|
MXPA03009935A
(es)
|
2001-04-30 |
2004-01-29 |
Pfizer Prod Inc |
Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp.
|
HUP0400263A2
(hu)
*
|
2001-06-21 |
2005-03-29 |
Pfizer Products Inc. |
Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
|
EP1404300B1
(en)
*
|
2001-06-22 |
2009-09-30 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
PL367674A1
(en)
*
|
2001-06-22 |
2005-03-07 |
Pfizer Products Inc. |
Pharmaceutical compositions of adsorbates of amorphous drug
|
EP1269994A3
(en)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
AU2002361811A1
(en)
|
2001-12-19 |
2003-07-09 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
HUP0500165A2
(en)
*
|
2001-12-19 |
2006-09-28 |
Atherogenics Inc |
Chalcone derivatives and their use to treat diseases
|
AU2002351748B2
(en)
*
|
2001-12-21 |
2009-07-09 |
Novo Nordisk A/S |
Amide derivatives as GK activators
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
DE60322665D1
(de)
*
|
2002-02-01 |
2008-09-18 |
Pfizer Prod Inc |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
|
RU2278659C9
(ru)
*
|
2002-02-01 |
2007-02-20 |
Пфайзер Продактс Инк. |
Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
|
JP2005523262A
(ja)
*
|
2002-02-01 |
2005-08-04 |
ファイザー・プロダクツ・インク |
薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
|
JP4881559B2
(ja)
*
|
2002-06-27 |
2012-02-22 |
ノボ・ノルデイスク・エー/エス |
治療薬としてのアリールカルボニル誘導体
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
US20090181966A1
(en)
*
|
2002-10-04 |
2009-07-16 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US7211672B2
(en)
*
|
2002-10-04 |
2007-05-01 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US7504508B2
(en)
|
2002-10-04 |
2009-03-17 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
ATE327977T1
(de)
*
|
2002-10-21 |
2006-06-15 |
Warner Lambert Co |
Tetrahydrochinolin-derivate als crth2 antagonisten
|
WO2004052863A1
(ja)
*
|
2002-12-06 |
2004-06-24 |
Kyowa Hakko Kogyo Co., Ltd. |
抗炎症剤
|
US20040181075A1
(en)
*
|
2002-12-19 |
2004-09-16 |
Weingarten M. David |
Process of making chalcone derivatives
|
WO2004056358A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
EP1435356A1
(en)
*
|
2003-01-06 |
2004-07-07 |
Warner-Lambert Company LLC |
Quinoline derivatives as CRTH2 antagonists
|
WO2004072042A2
(en)
*
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivative and their use for modulation of lxr activity
|
WO2004082675A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
|
AU2004222434B2
(en)
*
|
2003-03-17 |
2010-06-03 |
Japan Tobacco Inc. |
Pharmaceutical compositions of CETP inhibitors
|
CA2520405A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Pfizer Products Inc. |
1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
|
US20040204450A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
TWI494102B
(zh)
*
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
US7923467B2
(en)
|
2003-05-30 |
2011-04-12 |
Ranbaxy Laboratories, Inc. |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
ATE540671T1
(de)
|
2003-08-04 |
2012-01-15 |
Bend Res Inc |
Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
|
JP4536061B2
(ja)
|
2003-09-26 |
2010-09-01 |
日本たばこ産業株式会社 |
レムナントリポ蛋白生成阻害方法
|
JP2007507481A
(ja)
*
|
2003-09-30 |
2007-03-29 |
ファイザー・プロダクツ・インク |
Cetp阻害薬及びその代謝産物
|
EP2098512A1
(en)
*
|
2003-10-08 |
2009-09-09 |
Eli Lilly & Company |
Compounds and methods for treating dyslipidemia
|
US7390504B2
(en)
*
|
2003-11-07 |
2008-06-24 |
Jj Pharma, Inc. |
HDL-boosting combination therapy complexes
|
MXPA06007667A
(es)
*
|
2004-01-06 |
2006-09-01 |
Novo Nordisk As |
Heteroaril-ureas y su uso como activadores de glucocinasa.
|
KR101494067B1
(ko)
|
2004-03-05 |
2015-02-16 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
PL1732933T3
(pl)
|
2004-03-26 |
2008-12-31 |
Lilly Co Eli |
Związki do leczenia dyslipidemii
|
UA90269C2
(ru)
*
|
2004-04-02 |
2010-04-26 |
Мицубиси Танабе Фарма Корпорейшн |
Тетрагидрохинолиновые производные и способ их получения
|
TWI345568B
(en)
*
|
2004-04-02 |
2011-07-21 |
Mitsubishi Tanabe Pharma Corp |
Tetrahydronaphthyridine derivatives and a process for preparing the same
|
WO2006009819A1
(en)
*
|
2004-06-18 |
2006-01-26 |
Array Biopharma Inc. |
Inhibitors of cholesteryl ester transfer protien
|
KR100859223B1
(ko)
*
|
2004-06-24 |
2008-09-18 |
일라이 릴리 앤드 캄파니 |
이상지혈증 치료를 위한 화합물 및 방법
|
CA2570688A1
(en)
*
|
2004-06-24 |
2006-02-02 |
Eli Lilly And Company |
Compounds and methods for treating dyslipidemia
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
JP2008510835A
(ja)
*
|
2004-08-25 |
2008-04-10 |
エッセンシャリス,インク. |
カリウムatpチャンネル開放因子の製剤処方、及びその使用
|
WO2006033004A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Pfizer Products Inc. |
Quinoline compounds as cetp inhibitors
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
BRPI0518300A2
(pt)
*
|
2004-11-23 |
2008-11-11 |
Warner Lambert Co |
derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
|
WO2006069162A1
(en)
*
|
2004-12-20 |
2006-06-29 |
Reddy Us Therapeutics, Inc. |
Novel heterocyclic compounds and their pharmaceutical compositions
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
DK1848430T3
(da)
|
2004-12-31 |
2017-11-06 |
Dr Reddys Laboratories Ltd |
Nye benzylamin-derivativer som cetp-inhibitors
|
EP2548894A1
(en)
|
2005-02-03 |
2013-01-23 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
EP1861372A1
(en)
|
2005-02-24 |
2007-12-05 |
Millennium Pharmaceuticals, Inc. |
Pgd2 receptor antagonists for the treatment of inflammatory diseases
|
WO2006098394A1
(ja)
*
|
2005-03-14 |
2006-09-21 |
Japan Tobacco Inc. |
脂質吸収抑制方法および脂質吸収抑制剤
|
CN101212966B
(zh)
*
|
2005-07-01 |
2012-03-14 |
默沙东公司 |
合成cetp抑制剂的方法
|
US7999114B2
(en)
*
|
2005-07-08 |
2011-08-16 |
Novo Nordisk A/S |
Dicycloalkylcarbamoyl ureas as glucokinase activators
|
KR20080024211A
(ko)
*
|
2005-07-08 |
2008-03-17 |
노보 노르디스크 에이/에스 |
디시클로알킬 우레아 글루코키나제 활성제
|
MX2008000255A
(es)
*
|
2005-07-14 |
2008-04-02 |
Novo Nordisk As |
Activadores de urea glucocinasa.
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
JP4531027B2
(ja)
*
|
2005-09-29 |
2010-08-25 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4681526B2
(ja)
*
|
2005-09-29 |
2011-05-11 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP2009512715A
(ja)
|
2005-10-21 |
2009-03-26 |
ノバルティス アクチエンゲゼルシャフト |
レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
(3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
EP2404604B1
(en)
|
2006-01-05 |
2019-02-06 |
Essentialis, Inc. |
Salts of potassium ATP channel openers and uses thereof
|
UY30118A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compueto amina trisustituido
|
UY30117A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compuesto amina trisustituido
|
UY30244A1
(es)
|
2006-03-30 |
2007-11-30 |
Tanabe Seiyaku Co |
Un proceso para preparar derivados de tetrahidroquinolina
|
GB0615670D0
(en)
*
|
2006-08-07 |
2006-09-13 |
Syngenta Participations Ag |
Chemical compounds
|
US7750019B2
(en)
|
2006-08-11 |
2010-07-06 |
Kowa Company, Ltd. |
Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
|
AR063275A1
(es)
*
|
2006-10-12 |
2009-01-14 |
Epix Delaware Inc |
Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
WO2008079398A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
|
JP2010515701A
(ja)
*
|
2007-01-09 |
2010-05-13 |
ノボ・ノルデイスク・エー/エス |
ウレアグルコキナーゼアクチベーター
|
AU2008204530B2
(en)
|
2007-01-11 |
2013-08-01 |
Vtv Therapeutics Llc |
Urea glucokinase activators
|
CN101220021B
(zh)
*
|
2007-01-12 |
2010-12-08 |
上海医药工业研究院 |
4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
|
US7790737B2
(en)
|
2007-03-13 |
2010-09-07 |
Kowa Company, Ltd. |
Substituted pyrimidine compounds and their utility as CETP inhibitors
|
WO2008129951A1
(ja)
|
2007-04-13 |
2008-10-30 |
Kowa Company, Ltd. |
新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
|
CA2692160A1
(en)
*
|
2007-07-02 |
2009-01-08 |
Essentialis, Inc. |
Salts of potassium atp channel openers and uses thereof
|
KR101564793B1
(ko)
|
2007-11-05 |
2015-10-30 |
노파르티스 아게 |
고지질혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 cetp 억제제로서의 4-벤질아미노-1-카르복시아실-피페리딘 유도체
|
PT2229356E
(pt)
|
2007-12-03 |
2012-01-20 |
Novartis Ag |
Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
|
RU2010128543A
(ru)
|
2007-12-11 |
2012-01-20 |
Сайтопатфайндер, Инк. (Jp) |
Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
|
BRPI1012852A2
(pt)
|
2009-05-15 |
2018-06-19 |
Novartis Ag |
derivados de benzoxazolona como inibidores da sintase de aldoesterona
|
AU2010247414B2
(en)
|
2009-05-15 |
2013-08-01 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors
|
EP2435402B1
(en)
|
2009-05-28 |
2016-04-13 |
Novartis AG |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
AR076707A1
(es)
|
2009-05-28 |
2011-06-29 |
Novartis Ag |
Derivados amino-propionicos sustituidos como inhibidores de neprilisina
|
AR077208A1
(es)
*
|
2009-06-30 |
2011-08-10 |
Lilly Co Eli |
Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
|
EP2501678B1
(en)
|
2009-11-17 |
2015-09-23 |
Novartis AG |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(en)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazole derivatives as aldosterone synthase inhibitors
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
ES2648788T3
(es)
|
2011-01-26 |
2018-01-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
|
WO2012120414A2
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Inc. |
Edn3-like peptides and uses thereof
|
JP5629403B2
(ja)
|
2011-06-17 |
2014-11-19 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Crth2受容体モジュレータとしてのシクロアルキル縮合テトラヒドロキノリン
|
TWI537262B
(zh)
*
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
JP5964965B2
(ja)
|
2011-08-18 |
2016-08-03 |
ドクター レディズ ラボラトリーズ リミテッド |
コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
|
WO2013046045A1
(en)
|
2011-09-27 |
2013-04-04 |
Dr. Reddy's Laboratories, Ltd. |
5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
PT2956464T
(pt)
|
2013-02-14 |
2018-07-04 |
Novartis Ag |
Derivados de ácido bisfenil butanóico fosfónico substituído como inibidores de nep (endopeptidase neutra
|
CA2909442A1
(en)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
SG11201600208RA
(en)
|
2013-07-25 |
2016-02-26 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
AP2016009021A0
(en)
|
2013-07-25 |
2016-02-29 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
CN112755032A
(zh)
|
2014-08-28 |
2021-05-07 |
狄智玛制药私人有限公司 |
包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合
|
CA2959208C
(en)
|
2014-08-29 |
2023-09-19 |
Tes Pharma S.R.L. |
Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
KR20170103970A
(ko)
|
2015-01-23 |
2017-09-13 |
노파르티스 아게 |
개선된 반감기를 갖는 합성 아펠린 지방산 접합체
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
CA3093025A1
(en)
|
2018-06-12 |
2019-12-19 |
Vtv Therapeutics Llc |
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
|
CN113574055A
(zh)
|
2019-01-18 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|